SFRP1 and breast cancer: Consequently, cytosolic β‐CATENIN levels increase, which then translocates to the nucleus, interacts with T‐cell factor and lymphoid enhancer factor (TCF/LEF), and activates transcription of target genes such as c‐MYC, CYCLIN D1 and SURVIVIN. 29, 30, 31, 32WNT/β‐CATENIN signalling is known to be activated in 50% of breast cancer patients,33 and promoter DNA hypermethylation of pathway antagonists such as APC, DKK3, SFRP1 and SFRP2 has been reported in many breast cancer samples.34, 35, 36